ProteoGuide accelerates the translation of proteomics, unlocking the unlimited potential of biomarker discovery and resulting in validated, high-impact clinical diagnostics.
Across Europe, and particularly in the Netherlands, exceptional biobanks and research programs continuously generate high-quality biomarker discoveries. Yet, without a structured translational pathway, the vast majority of these insights never reach clinical practice.
Consequently, valuable intellectual property is lost and long-term socio-economic
impact escapes potential clinical translation.
ProteoGuide bridges the gap between scientific biomarker discovery and clinical
application through a fully integrated, standardized development model.
Direct Biobank Access
Structured collaborations enabling access to unique, high-quality patient cohorts.
Advanced Proteomics
State-of-the-art mass spectrometry and high-throughput proteomics platform.
Clinical & Utility Validation
Rigorous analytical triage combined with robust clinical validation pathways.
Standardized Assay Development
Standardizing raw discoveries into industrially scalable, regulatory-compliant assays.
From our active biomarker programs, we systematically select, validate,
and develop the most promising candidates into clinical diagnostic
products, ensuring maximum translation potential.
ProteoGuide is designed to solve the core roadblock in biomarker translation:
the lack of structural alignment and intellectual property control between
academia, patient biobanks, and market participants.
Structured access to biobanks through formal research collaborations.
Foreground IP generated within the programs is developed and held by ProteoGuide.
Exclusive commercialization rights for all resulting diagnostics assays.
Predefined regulatory and licensing structures with global assay partners.
Prevention of asset or IP leakage through coordinated, safe publication schemes.
ProteoGuide aligns scientific discovery with long-term commercial value
creation, protecting IP before it is lost to premature publication.
ProteoGuide initiates and operates structured validation portfolios across
strategic medical fields, including oncology, prenatal disorders, and clinical
immunology.
A validated biomarker panel enables early, high-precision
identification of high-risk pregnancies, allowing timely therapeutic
intervention and improved clinical outcomes.
A predictive serum biomarker-based diagnostic assessment to
reduce clinical uncertainty, clinical anxiety, and direct early
supportive prenatal care pathways.
ProteoGuide generates robust socio-economic value through a dual-faceted
approach of asset product development and structured licensing partnerships:
RUO kits enabling rapid market entry and analytical validation.
CE-marked IVD diagnostics for standard automated platforms.
Custom assay licensing and high-value royalty agreements.
Strategic co-development partnerships with diagnostic corporates.
A highly capital-efficient, portfolio-driven model designed to achieve
clear diagnostic and value inflection points.
Experienced Leadership in Diagnostics
and Life Sciences
Experienced executive and entrepreneur in life sciences and diagnostics, with a strong track record in building and scaling organizations.
Serial entrepreneur in bio-analytics and translational research, with deep expertise in proteomics and biomarker discovery.
Diagnostics industry leader with extensive experience in assay development, manufacturing, and commercialization.
Collaborate with ProteoGuide to translate strategic biomarker insights into validated clinical applications.
Join the development of a highly scalable diagnostics pipeline with strong IP and robust commercial potential.
